Thomas Norman

Thomas Norman has advanced Perturb-seq methodology, which combines CRISPR perturbations with single-cell RNA-seq readout to measure the transcriptional consequences of genetic perturbations at single-cell resolution in cancer cells. His work on combinatorial Perturb-seq screens, perturbing multiple genes simultaneously, has enabled systematic mapping of genetic interaction networks in cancer, revealing epistatic relationships between oncogenes and tumor suppressors that determine cell fate decisions. He has applied these approaches to identify synthetic lethal gene pairs and characterize the transcriptional programs underlying drug resistance in cancer. His methods bridge functional genomics and single-cell biology for cancer gene discovery.